

DAFTAR PUSTAKA

1. Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, et al. Correlation between serum PSA and cancer volume in prostate glands of different sizes. *Urology*. 2010;76(5); 1072-6
2. Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, et al. Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index? *Eur Urol* 2002; 42:7-11.
3. Coban, S., Doluoglu, O.G., Keles, I., Demirci, H., Turkoglu, A.R., Guzelsoy, M., Karalar, M. and Demirbas, M., 2016. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia. *The aging male*, 19(2), pp.124-127.
4. Deori, R., Das, B. and Rahman, M.A., 2017. A Study of Relationship of Prostate Volume, Prostate Specific Antigen and age in Benign Prostatic Hyperplasia. *Journal of Contemporary Medical Research*, 4(7), pp.1582-1586.
5. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms : Prevalence and Incident Rates. *Urologic Clinics of North America*. *Urol Clin N Am*. 2016; 43(3): 289–297
6. Epstein JI. Pathology of Prostatic Neoplasia. In Campbell M, Wein A, Kavoussi L, Walsh P. *Campbell-Walsh urology*. Philadelphia: Elsevier; 2016; p2593-600



- differentiation. *The American journal of surgical pathology*, 38(6), p.756.Epstein,
8. J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R., Humphrey, P.A. and Grading Committee, 2016. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. *The American journal of surgical pathology*, 40(2), pp.244-252.
 9. Hagjer, S., Adhikari, H. and Ahmed, A., 2018. Correlation of Prostatic Volume Assessed By Transabdominal USG with IPSS and PSA Level in Blood in Benign Prostatic Hyperplasia. *Paripex-Indian Journal of Research*, 7(1).
 10. Hari, J.P., Ratan, R., Takkar, P. and Shergill, K.K., 2018. Relationship Between Grades of Prostatomegaly on DRE and Prostate Volume on Sonography With Lower Urinary Tract Symptoms: To Believe Your Finger or The Ultrasound Probe!!!. *International Journal of Scientific Research*, 7(3).
 11. Hulley SB, Cummings SR, Browner WS, Grady D, Newman TB. Designing clinical research : an epidemiologic approach. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p 79.
 12. Köpke TE. Negative predictive value of systematic ultrasound-guided prostate biopsy: which tumours do we miss? - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2016 [cited 4 October 2016]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20592386>



Prostatic Hyperplasia at Bhayangkara Hospital Mataram. Journal of Medicine & Health, 1(6).

14. Kuriyama, M., Ueno, K., Uno, H., Kawada, Y., Akimoto, S., Noda, M., Nasu, Y., Tsushima, T., Ohmori, H., Sakai, H. and Saito, Y., 1998. Clinical Evaluation of Serum Prostate-Specific Antigen-Alpha1-Antichymotrypsin Complex Values in Diagnosis of Prostate Cancer: A Cooperative Study. *International journal of urology*, 5(1), pp.48-54.
15. Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. *Urology*. 1996; 47: 38-42.
16. Loeb S, Eastham JA. Diagnosis and Staging of Prostate Cancer. In Campbell M, Wein A, Kavoussi L, Walsh P. *Campbell-Walsh urology*. Philadelphia: Elsevier; 2016; p2601-9
17. Lojanapiwat B, Anuttrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. *Prostate International*. 2014;2(3):133-9.
18. Lotan, T.L. and Epstein, J.I., 2010. Clinical implications of changing definitions within the Gleason grading system. *Nature Reviews Urology*, 7(3), p.136.



htar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, Poernomo BB, Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak. Ikatan Ahliologi Indonesia. 2015. Diunduh 4 November 2016.

20. Mochtar CA, Umbas R, Soebadi DM, Rasyid N, Noegroho BS, Poernomo BB, et al. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak. Iakatan Ahli Urologi Indonesia. 2015. Diunduh 4 November 2016. Tersedia dari: [http://www.iaui.or.id/ast/file/Guideline_BPH_\(2015\).pdf](http://www.iaui.or.id/ast/file/Guideline_BPH_(2015).pdf)
21. Morgan TM, Palapattu GS, Partin AW, Wei JT. Prostate Cancer Tumor Markers. In Campbell M, Wein A, Kavoussi L, Walsh P. Campbell-Walsh urology. Philadelphia: Elsevier; 2016; p2565-77
22. Murray, N.P., Reyes, E., Orellana, N., Fuentealba, C. and Jacob, O., 2015. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy. *Asian Pac J Cancer Prev*, 16, pp.601-606.
23. Netto, G.J. and Epstein, J.I., 2010. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. *Pathology*, 42(4), pp.384-394.
24. Powell, I.J., Bock, C.H., Ruterbusch, J.J. and Sakr, W., 2010. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. *The Journal of urology*, 183(5), pp.1792-1797.
25. Presti, J.C. Neoplasms of the Prostate Cancer.In: Tanagho EA, McAninch JW. *Ph's General Urology*, Sixteenth edition. USA: The McGraw-Hill Companies, 2010. p367-84.



26. Putra IBOW, et al. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. *Prostate Int.* 2016. Available from: <http://dx.doi.org/10.1016/j.prnil.2016.03.002>
27. Putra, I.B.O., Hamid, A.R., Mochtar, C.A. and Umbas, R., 2016. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. *Prostate international*, 4(2), pp.43-48.
28. Rahardjo D, Birowo P, Pakasi L. Correlation between prostate volume, prostate specific antigen level, prostate specific antigen density and age in the benign prostate hyperplasia patients. *Med J Indones*.1999;260.
29. Roehrborn, CG. et al. 2016. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History in Campbell – Walsh Urology. 11th edition. Philadelphia: Elsevier Saunders
30. Tomlins, S.A., Bjartell, A., Chinnaiyan, A.M., Jenster, G., Nam, R.K., Rubin, M.A. and Schalken, J.A., 2009. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. *European urology*, 56(2), pp.275-286.
31. Udeh E,Dakum N, Amu O, Ramyl V. Correlation between serum prostate specific antigen and prostate volume in Nigerian men with biopsy proven benign prostatic hyperplasia : prospective study). *Int J Urol*. 2009;7(2)
32. Xu, N., Chen, S.H., Xue, X.Y., Wei, Y., Zheng, Q.S., Li, X.D., Huang, J.B., Cai, H., Sun, X.L. and Lin, Y.Z., 2017. Older age and larger prostate volume



associated with stress urinary incontinence after plasmakinetic enucleation of the prostate. *BioMed research international*, 2017.

33. Zor, M., Kaya, E. and Bedir, S., 2018. Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?. *GULHANE MEDICAL JOURNAL*, 60(1).



Optimization Software:
www.balesio.com